title: Decitabine: a promising epi-immunotherapeutic agent in solid tumors.
abstract: The incidence of malignancies is increasing worldwide. Despite early detection, surgical resection, chemotherapy and radiotherapy, numerous patients continue to die from metastasis or recurrence. The immune system has the capacity to eradicate cancer cells; however, many tumors, especially solid tumors, present considerable challenges that render immune cells ineffectual, making cancer cells almost 'invisible' to the immune system. Compelling evidence has demonstrated that DNA methylation is involved in tumor development and progression, leading to the impaired immunogenicity and immune recognition of cancer cells. The hypomethylating agent decitabine has been shown to have therapeutic effects in malignancies and exhibits an effective immune efficacy in eliminating cancer cells. Based on the hypomethylating and immune remodeling effects of decitabine, we propose in this review that decitabine can be considered an epi-immunotherapeutic agent. We summarize the results of recent preclinical studies and clinical trials for decitabine and discuss the connections among its hypomethylating effect, immune-activated mechanisms and clinical activity in solid tumors, keeping in mind the goal of optimizing dosing schedules.
authors.affiliation: Department of Molecular Biology, School of Life Sciences, Chinese PLA General Hospital, Institute of Basic Medicine, Beijing, 100853, China.
authors.forename: Xiang
authors.initials: X
authors.lastname: Li
authors.forename: Qian
authors.initials: Q
authors.lastname: Mei
authors.forename: Jing
authors.initials: J
authors.lastname: Nie
authors.forename: Xiaobing
authors.initials: X
authors.lastname: Fu
authors.forename: Weidong
authors.initials: W
authors.lastname: Han
mesh_terms: D000818:Animals; D001374:Azacitidine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D063646:Carcinogenesis / Q000187:drug effects; D002986:Clinical Trials as Topic; D019175:DNA Methylation / Q000187:drug effects; D015254:DNA Modification Methylases / Q000037:antagonists & inhibitors; D000077209:Decitabine; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D019139:Tumor Escape / Q000187:drug effects
chemical_list: D000077209:Decitabine; D015254:DNA Modification Methylases; D001374:Azacitidine
keywords: HLA class I; cancer testis antigen; co-stimulatory molecules; decitabine; immune response; immunotherapy; methylation